SR141716 IN FEMALE BABOONS

雌性狒狒中的 SR141716

• 批准号: 7957937
• 负责人: RAUL A BASTARRACHEA
• 金额: $ 11.45万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-06 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7957937
• 关键词: Address; Animals; Anti-Obesity Agents; Banana; Blood specimen; Butter; Computer Retrieval of Information on Scientific Projects Database; Data; Dose; Drug Kinetics; Dyslipidemias; Eating; Fatty acid glycerol esters; Female; Funding; Future; Grant; Hour; Individual; Institution; Investigation; Lipids; Liver; Measures; Metabolic; Metabolic Pathway; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Overweight; Patients; Peanuts - dietary; Pharmaceutical Preparations; Primates; Protocols documentation; Research; Research Personnel; Resources; SR141716; Sampling; Solutions; Source; System; Treatment Protocols; United States National Institutes of Health; Weight Gain; design; diet and exercise; glucose metabolism; lipid metabolism; nonhuman primate; receptor; rimonabant; uptake

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The present study will be undertaken to provide non-human primate data on the uptake, circulatory dynamics, and clearance (pharmacokinetics) of an orally-administered solution of the drug Rimonabant (SRI 417 16). Rimonabant is a recently developed anti-obesity drug that acts on a group of receptors known as the fll1docannabinoid receptors. This system of receptors is overactive in obese individuals and is related to increased food intake, altered lipid and glucose metabolism, and weight gain. Future studies are required to determine the broader metabolic effects of this agent. The present study will provide data to design the dosing protocols for future non-human primate studies that address the effects of Rimonabant on liver fat content and lipid metabolism. Three different doses of tile drug will be given to animals on three different occasions in the form of a sweet treat (banana and peanut butter). Blood samples (10) will be collected periodically for 48 hours following each administration of the agent. Concentrations of active Rimonabant will be measured in these samples and will provide the pharmacokinetic data necessary to determine the optimal dosing regimen for future studies. Presently, Rimonabant is recommended, in conjunction with diet and exercise, in obese patients and in overweight patients with type 2 diabetes or dyslipidemia. The present study and associated future investigations will provide much needed information of the effects of this agent on multiple metabolic pathways and potentially provide information on broader indications for its use.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 本研究将进行，以提供有关药物rimonabant口服的溶液的摄取，循环动力学和清除率（药代动力学）的非人类灵长类动物数据（SRI 417 16）。 Rimonabant是一种最近发育的抗肥胖药物，作用于一组称为FLL1Docantabinoid受体的受体。这种受体系统在肥胖个体中过度活跃，与食物摄入量增加，脂质和葡萄糖代谢的改变以及体重增加有关。需要未来的研究来确定该药物的更广泛的代谢作用。本研究将为未来的非人类灵长类动物研究提供数据，以设计剂量方案，以解决利莫班班对肝脏脂肪含量和脂质代谢的影响。三种不同的场合将以甜食（香蕉和花生酱）的形式给动物三种不同剂量的瓷砖药物。每次给药后，将定期收集血液样本（10）48小时。将在这些样品中测量活性轮足症的浓度，并将提供确定未来研究的最佳剂量方案所需的药代动力学数据。目前，对于肥胖患者以及2型糖尿病或血脂异常超重的患者，建议使用饮食和运动。本研究和相关的未来研究将提供急需的信息，以了解该代理对多种代谢途径的影响，并有可能提供有关其使用的更广泛指示的信息。